Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities Over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities

Werewolf Therapeutics Appoints Meeta Chatterjee, Ph.D., to its Board of Directors

Posters Detail Preclinical Data on the Company's WTX-124 and WTX-330 Molecules for the Potential Treatment of Cancer Posters Detail Preclinical Data on the Company's WTX-124 and WTX-330 Molecules for the Potential Treatment of Cancer

Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced it will present at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13-15.

Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference

Merck

Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizumab). WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate.

Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck

Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program

CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today provided a business update and reported financial results for the quarter ended June 30, 2021.

Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update

Rain Therapeutics

In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outperformed the Standard & Poor's 500 index benchmark by at least 10% over the past month are Werewolf Therapeutics Inc. ( HOWL , Financial), Ecit AS ( OSL:ECIT , Financial), Effnetplattformen Holding AB ( OSTO:EFFH , Financial) and Rain Therapeutics Inc. ( RAIN , Financial) according to the All-in-One Screener, a Premium feature of GuruFocus.

4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that it will be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution on June 28, 2021.

Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index

- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -

Werewolf Therapeutics Reports First Quarter 2021 Financial Results

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics, will present at Jefferies Virtual Healthcare Conference on Thursday, June 3rd, at 11 am ET.

Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021

Werewolf Therapeutics (HOWL) stock is doing incredibly well for its first day of trading on the Nasdaq following its IPO. The post Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of Trading appeared first on InvestorPlace.

Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of Trading

News for Werewolf Therapeutics Stock (HOWL)